Skip to content

Impact of nSIMV versus CPAP in Preterm Infants During the Weaning Phase After Respiratory Distress Syndrome – A Prospective Randomized Clinical Cross-over Study

Impact of nSIMV versus CPAP in Preterm Infants During the Weaning Phase After Respiratory Distress Syndrome – A Prospective Randomized Clinical Cross-over Study - nSIMV-CPAP Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00035876
Enrollment
24
Registered
2025-01-13
Start date
2025-02-12
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

P22.0

Interventions

Group 1: nSIMV - Nasal synchronized intermittent mechanical ventilation with fixed parameters: Frequency: 40/min. Inspiratory time (I-time): 0.3 seconds. PEEP: Adjusted to match the mean airway pressu

Sponsors

Universistätsklinikum Ulm
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Days to No maximum

Inclusion criteria

Inclusion criteria: - Preterm infants with a gestational age 20 seconds) and/or bradycardia (heart rate <100/min) within the 12 hours prior to study entry. - No escalation of non-invasive ventilation in the 12 hours prior to study entry due to events such as SpO2 <70% or heart rate <100/min. - Written informed consent from the legal guardians.

Exclusion criteria

Exclusion criteria: - Preterm and newborn infants with severe malformations significantly impairing respiratory regulation (e.g., severe CNS malformations), lung function (e.g., pulmonary hypoplasia, pneumothorax, diaphragmatic hernia), or circulatory function (e.g., congenital cyanotic heart defects, severe septic shock). - Postnatal age 60%. - Escalation of non-invasive ventilation in the 12 hours prior to study entry due to events (e.g., SpO2 <70% or heart rate <100/min). - Planned blood transfusion or surgery during the study period. Study start <48 hours after immunization. - ROP examination (Retinopathy of Prematurity) on study days.

Design outcomes

Primary

MeasureTime frame
Duration of pulse oximetry-measured oxygen saturation (SpO2) within the target range of 88-95%, expressed as a percentage of total time.

Secondary

MeasureTime frame
- Number and duration of episodes with SpO2 95% - Average inspiratory oxygen concentration (FiO2) - Cerebral tissue oxygenation (SctO2) and related cerebral parameters - Variability of oxygen saturation and additional measures such as the Silverman score, abdominal

Countries

Germany

Contacts

Public ContactAntje Westhoff

Klinik für Kinder-und Jugendmedizin, Sektion Neonatologie und pädiatrische Intensivmedizin

antje.westhoff@uniklinik-ulm.de073150057470

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026